Norwich Single-Cell Symposium 2019, Earlham Institute, single-cell genomics technologies and their application in microbial, plant, animal and human health and disease, October 16-17, 2019, 10AM-5PM
Reporter: Aviva Lev-Ari, PhD, RN
4.1.7 Norwich Single-Cell Symposium 2019, Earlham Institute, single-cell genomics technologies and their application in microbial, plant, animal and human health and disease, October 16-17, 2019, 10AM-5PM, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 4: Single Cell Genomics
Organiser:
Enquiries:
Earlham Institute
Norwich Research Park
Norwich, Norfolk
NR4 7UZ
UK
About the event.
Single cell genomic technologies continue to develop at pace, generating new insights into cellular diversity within living systems. The Norwich Single Cell Symposium, hosted annually at EI, aims to bring together researchers applying single cell technologies across a wide range of species.
Now in its third year, the Symposium covers single-cell genomics technologies and their application in microbial, plant, animal and human health and disease. The symposium offers a forum for researchers to discuss the latest developments in single-cell genomics, and network with other researchers with the intention of catalysing future development and application of single-cell genomics across the UK.
This year, the event will take place over two days and feature talks from invited speakers and selected abstracts, and we are keen to capture as broad a range of single-cell applications as possible.
Topics to be covered include:
- Single cell genomics in plant and microbial research
- Single cell genomics in health, disease and development
- Single cell informatics
- Single cell technology development
Abstracts
This year we are offering the opportunity to present posters on your research during the canapes and networking session. Submission deadline for abstracts is 1 September 2019 (23.59 GMT).
All abstracts must be submitted electronically as part of your registration. Submissions via email will not be accepted
Abstract limits are 250 words (excluding title, authors and affiliations)
Presenting author should be highlighted in bold
Abstracts will be reviewed within 14 days of the submission deadline and you will be informed of the outcome shortly thereafter
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.